AB-101 + bendamustine + rituximab

AB-101 + bendamustine + rituximab is a combination therapy under clinical investigation for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) of B-cell origin, including diffuse large B-cell lymphoma (DLBCL). **AB-101** is an off-the-shelf, allogeneic "natural killer" (NK) cell therapy designed to enhance anti-cancer immunity. **Bendamustine** is a synthetic alkylating agent with unique cytotoxic properties disrupting DNA in malignant B cells. **Rituximab** is a monoclonal antibody targeting CD20 antigens on B lymphocytes, causing cell lysis via immune-mediated mechanisms. The combination seeks to leverage cellular cytotoxicity (via AB-101), DNA damage (via bendamustine), and targeted B-cell depletion (via rituximab) for greater efficacy against B-cell lymphomas, particularly in cases where disease is relapsed or refractory to prior therapies[1][3].